ArticleVirchows Archiv : an international journal of pathology2026
Nuclear grading of myxoid liposarcoma robustly predicts patient outcome: a study of 280 patients.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myxoid liposarcoma (MLPS) exhibits variable morphology and clinical behavior. Current grading systems, which rely on the proportion of round cell areas, were developed for resections, rather than core biopsies. Additionally, criteria for round cell and "transitional" areas are subjective/poorly reproducible. It has recently been suggested that nuclear grading may be superior to traditional grading in predicting the behavior of MLPS. We compared nuclear and cellularity-based grading in a large, multinational MLPS cohort. 280 MLPS (1990-2025) were reviewed; nuclear grade was assigned using a slight modification of the Kawaguchi et al. system. Disease‑specific survival (DSS), metastasis‑free survival (MFS), and disease‑free survival (DFS) were estimated and the performance of both grading systems was compared. Tumors occurred in 152 males/128 females (median 45 years of age; range 15-91 years) and predominantly involved proximal deep soft tissues. Initial diagnoses were made with needle core (149 cases) and open biopsies (131 cases). DDIT3 rearrangement was documented in 195 tumors. Nuclear grades were 1 (71 cases), 2 (121 cases) and 3 (88 cases); grades 1 and 2 were considered "low-grade" and grade 3 "high-grade". Both systems assessed 192 (69%) and 88 (31%) tumors to be low and high-grade, respectively, although there was not perfect overlap. Clinical follow-up (280 patients; median 68 months, range: 3-355 months) showed 33 local recurrences, 96 distant metastases and 63 cancer-specific deaths. Tumors with low nuclear grade demonstrated significantly better DSS, MFS and DFS; those with low conventional grade did not. Identical results were seen with tumors diagnosed by needle biopsy (149 cases). The Harrell's C-index demonstrated nuclear grading to be superior in the prediction of DSS, MFS and DFS. We conclude that nuclear grading demonstrates superior prognostic performance over conventional grading, including in tumors diagnosed by needle biopsy. These results argue for more widespread adoption of nuclear grading in MLPS prognostication.
Indexed as
Identifiers
42873287What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.